Key result
Dantrolene stops exercise-induced VT in RyR2 S2246L mutants by correcting erroneous Ca2+ channel activation.
Why the study?
The molecular mechanism by which catecholaminergic polymorphic ventricular tachycardia is induced by single amino acid mutations within the cardiac ryanodine receptor remains elusive.
Population
Knockin mouse model expressing human RyR2 mutant S2246L and knockin cardiomyocytes
Comparison
RyR2 S2246L mutant knockin mice or cardiomyocytes vs wild-type or dantrolene treatment
Design
Preclinical animal and cellular experimental study
Authors
Loading...
Dantrolene suppressed VT in S2246L mice; hypothesis-generating for CPVT therapy, should not yet change practice.
The S2246L mutation in RyR2 causes CPVT through defective interdomain interactions that lead to aberrant diastolic Ca2+ release, a mechanism that can be reversed by dantrolene.
Suetomi et al. (2011) studied Catecholaminergic polymorphic ventricular tachycardia. S2246L mutation in RyR2 vs. Wild-type was evaluated on Ventricular tachycardia after exercise and Ca2+ spark frequency. The S2246L mutation in RyR2 causes defective interdomain interactions leading to erroneous Ca2+ channel activation and exercise-induced ventricular tachycardia, which was stopped by dantrolene.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: